First National Corp’s Global Blood Therapeutics, Inc. GBT Stock Holding History

First National Corp’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-300	Closed	-$16K	–	463
2019 Q1	$16K	Hold	300	–	–	0.01%	304
2018 Q4	$12K	Buy	+300	New	+$11.2K	0.01%	337

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

First National Corp's GBT Position: Q2 2019 in Review

First National Corp sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2019, closing a stake of 300 shares — an estimated $16K sold.

First National Corp first reported a position in GBT in Q4 2018 and held it in 2 quarters. The position peaked at $16K in Q1 2019. 223 funds tracked by Wall St. Rank hold GBT as of Q2 2019.

First National Corp reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
First National Corp sold 300 Global Blood Therapeutics, Inc. shares in Q2 2019, an estimated $16K.
First National Corp first reported a position in Global Blood Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
First National Corp's Global Blood Therapeutics, Inc. position peaked at $16K in Q1 2019.
223 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2019.

Based on First National Corp's 13F filing for Q2 2019, filed 30 Jul 2019.